Skip to main content

Advertisement

Table 3 Summary of treatment-emergent and treatment-related adverse events by preferred term reported by at least two patients in either treatment group (proof-of-concept component)

From: Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial

Adverse events, number (percentage) Placebo Maraviroc 300 mg BID
  Treatment-emergent (n= 33) Treatment-related (n= 33) Treatment-emergent (n= 77) Treatment-related (n= 77)
Worsening rheumatoid arthritis 8 (24.2) 1 (3.0) 3 (3.9) 0
Constipation 0 0 6 (7.8) 4 (5.2)
Nausea 0 0 4 (5.2) 3 (3.9)
Chills 1 (3.0) 0 2 (2.6) 2 (2.6)
Dizziness 1 (3.0) 1 (3.0) 2 (2.6) 1 (1.3)
Fatigue 0 0 3 (3.9) 1 (1.3)
Edema peripheral 2 (6.1) 2 (6.1) 0 0
Headache 1 (3.0) 0 2 (2.6) 1 (1.3)
Diarrhea 2 (6.1) 0 1 (1.3) 1 (1.3)
Upper respiratory tract infection 0 0 3 (3.9) 0
Orthostatic hypotension 0 0 2 (2.6) 1 (1.3)
Dyspepsia 0 0 2 (2.6) 1 (1.3)
Pyrexia 0 0 2 (2.6) 1 (1.3)
Respiratory tract infection 0 0 2 (2.6) 0
Influenza 2 (6.1) 0 0 0
  1. BID, twice daily.